Potent antiviral activities of type I interferons to SARS-CoV-2 infection

Emily Mantlo; Natalya Bukreyeva; Junki Maruyama; Slobodan Paessler; Cheng Huang

doi:10.1101/2020.04.02.022764

Potent antiviral activities of type I interferons to SARS-CoV-2 infection

Emily Mantlo, Natalya Bukreyeva, Junki Maruyama, Slobodan Paessler, Cheng Huang

Pathology

Research output: Contribution to journal › Article › peer-review

Abstract

The ongoing historic outbreak of COVID-19 not only constitutes a global public health crisis, but also carries a devastating social and economic impact. The disease is caused by a newly identified coronavirus, Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the remarkable sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α at a concentration of 50 international units (IU) per milliliter drastically reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potent efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.

Original language	English (US)
Journal	Unknown Journal
DOIs	https://doi.org/10.1101/2020.04.02.022764
State	Published - Apr 5 2020

Keywords

Antiviral therapy
COVID-19
Innate immune
Interferon
SARS-CoV-2

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Agricultural and Biological Sciences(all)
Immunology and Microbiology(all)
Neuroscience(all)
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.1101/2020.04.02.022764

Fingerprint Dive into the research topics of 'Potent antiviral activities of type I interferons to SARS-CoV-2 infection'. Together they form a unique fingerprint.

Cite this

@article{2252c80b41244b1e83200f5c5dfd5f48,

title = "Potent antiviral activities of type I interferons to SARS-CoV-2 infection",

abstract = "The ongoing historic outbreak of COVID-19 not only constitutes a global public health crisis, but also carries a devastating social and economic impact. The disease is caused by a newly identified coronavirus, Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the remarkable sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α at a concentration of 50 international units (IU) per milliliter drastically reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potent efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.",

keywords = "Antiviral therapy, COVID-19, Innate immune, Interferon, SARS-CoV-2",

author = "Emily Mantlo and Natalya Bukreyeva and Junki Maruyama and Slobodan Paessler and Cheng Huang",

note = "Publisher Copyright: The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = apr,

day = "5",

doi = "10.1101/2020.04.02.022764",

language = "English (US)",

journal = "Molecular Oncology",

issn = "1574-7891",

publisher = "Elsevier",

}

TY - JOUR

T1 - Potent antiviral activities of type I interferons to SARS-CoV-2 infection

AU - Mantlo, Emily

AU - Bukreyeva, Natalya

AU - Maruyama, Junki

AU - Paessler, Slobodan

AU - Huang, Cheng

N1 - Publisher Copyright: The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/4/5

Y1 - 2020/4/5

N2 - The ongoing historic outbreak of COVID-19 not only constitutes a global public health crisis, but also carries a devastating social and economic impact. The disease is caused by a newly identified coronavirus, Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the remarkable sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α at a concentration of 50 international units (IU) per milliliter drastically reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potent efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.

AB - The ongoing historic outbreak of COVID-19 not only constitutes a global public health crisis, but also carries a devastating social and economic impact. The disease is caused by a newly identified coronavirus, Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the remarkable sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α at a concentration of 50 international units (IU) per milliliter drastically reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potent efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.

KW - Antiviral therapy

KW - COVID-19

KW - Innate immune

KW - Interferon

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85098906170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85098906170&partnerID=8YFLogxK

U2 - 10.1101/2020.04.02.022764

DO - 10.1101/2020.04.02.022764

M3 - Article

AN - SCOPUS:85098906170

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

ER -